Modex, a Cloud-based, Centralized Health Economic Model Marketplace to Reduce Costs and Enhance Equity in Cancer
NCT07361458 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9
Last updated 2026-01-23
Summary
The investigators intend to create and test an interactive prototype of an online health economic model platform, ModEx™ (renamed HModEx®), to house oncology models. The primary objective is to create the HModEx® health economic model platform. The secondary objective is to conduct usability testing of search, quality and collaboration on the HModEx® prototype for 20 oncology health economic models with expert advisory panel participants.
Conditions
Interventions
- OTHER
-
open source health economic models
open source health economic models
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Arnold Consultancy & Technology, LLC
lead OTHER
Principal Investigators
-
Renee JG Arnold, PharmD · Arnold Consultancy & Technology, LLC
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 25 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-12-01
- Primary Completion
- 2025-11-20
- Completion
- 2025-11-20
Countries
- United States
Study Locations
More Related Trials
-
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
NCT01363232 ·Status: COMPLETED ·Phase: PHASE1
-
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00119236 ·Status: COMPLETED ·Phase: PHASE1
-
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
NCT00004241 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly
NCT02360345 ·Status: COMPLETED ·Phase: PHASE1
-
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
NCT00003109 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors
NCT00003711 ·Status: COMPLETED ·Phase: PHASE1
-
HW071021 Monotherapy in Patients With Advanced Solid Tumors
NCT06882135 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
NCT03634982 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
NCT00179699 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy
NCT01921998 ·Status: SUSPENDED
-
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00608361 ·Status: COMPLETED ·Phase: PHASE1
-
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
NCT04891718 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02503709 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05487235 ·Status: COMPLETED ·Phase: PHASE1
-
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
NCT02517398 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
NCT00394446 ·Status: COMPLETED ·Phase: PHASE1
-
A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
NCT05908773 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
NCT00003970 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
NCT04083651 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT06724016 ·Status: RECRUITING ·Phase: PHASE1
-
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
NCT07136779 ·Status: RECRUITING ·Phase: PHASE1/PHASE2